lnu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Dose patterns among patients using low-dose buprenorphine patches.
Nordic Health Economics AB.ORCID-id: 0000-0002-0518-6196
Vise andre og tillknytning
2013 (engelsk)Inngår i: Pain medicine (Malden, Mass.), ISSN 1526-2375, E-ISSN 1526-4637, Vol. 14, nr 9, s. 1374-80Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

OBJECTIVE: The objective of this study was to investigate the dose pattern of low-dose buprenorphine patches among patients in Swedish clinical practice. The clinical experts among the coauthors interpreted the results in relation to possible indications of development of tolerance and/or dependence/addiction.

DESIGN AND SETTING: This was a nationwide, observational study using data from the Swedish Prescribed Drug Register.

SUBJECTS: Individuals who were dispensed the low-dose buprenorphine patches continuously for more than 24 weeks during July 1, 2005 to February 28, 2011 were included.

METHODS: The dose pattern was analyzed as the change in dose over time for each patient: 1) the dose at baseline compared with each of the following 8-week intervals, and 2) the dose at baseline compared with the dose during the patients' last treatment period.

RESULTS: The majority of the patients were female (74%), and most were 75 years and older (69%). The median treatment duration was 260 days, and 4% and 1% of patients remained on continuous treatment for 2 and 3 years, respectively. The mean dose was 11 μg/h at baseline, and 15 μg/h during the patients' last treatment period. The average dose increased by 4 μg/h during the patients' entire treatment course.

CONCLUSIONS: The average dose increased by 4 μg/h during the patients' treatment course, which lasted on an average of 260 days. From a clinical perspective, the dose increase of 4 μg/h is low and does not suggest dependence/addiction, as also supported by the low proportion of patients remaining on continuous treatment.

sted, utgiver, år, opplag, sider
2013. Vol. 14, nr 9, s. 1374-80
HSV kategori
Identifikatorer
URN: urn:nbn:se:lnu:diva-29976DOI: 10.1111/pme.12142PubMedID: 23692014OAI: oai:DiVA.org:lnu-29976DiVA, id: diva2:659450
Tilgjengelig fra: 2013-10-25 Laget: 2013-10-25 Sist oppdatert: 2017-12-06bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Ericson, Lisa

Søk i DiVA

Av forfatter/redaktør
Ericson, Lisa
I samme tidsskrift
Pain medicine (Malden, Mass.)

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 65 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf